Mesoblast (NASDAQ:MESO) Shares Gap Up – What’s Next?

Mesoblast Limited (NASDAQ:MESO) gapped up before the market opened on Thursday . The stock had previously closed at $13.54, but opened at $13.97. Mesoblast shares last traded at $13.78, with a volume of 13,626 shares traded.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on MESO. Piper Sandler reaffirmed an “overweight” rating and set a $24.00 target price (up from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. Cantor Fitzgerald raised Mesoblast to a “strong-buy” rating in a research report on Tuesday, March 4th. Finally, Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Mesoblast Trading Up 1.7 %

The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The firm’s 50-day moving average price is $16.79 and its 200 day moving average price is $12.81.

Hedge Funds Weigh In On Mesoblast

Large investors have recently modified their holdings of the stock. Strategic Financial Concepts LLC bought a new stake in shares of Mesoblast during the 4th quarter valued at about $2,744,000. Jane Street Group LLC grew its position in shares of Mesoblast by 46.4% during the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after buying an additional 26,959 shares during the last quarter. Clayton Financial Group LLC bought a new stake in shares of Mesoblast during the 4th quarter valued at about $275,000. Ballentine Partners LLC bought a new stake in shares of Mesoblast during the 4th quarter valued at about $222,000. Finally, Lindbrook Capital LLC grew its position in shares of Mesoblast by 70.9% during the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock valued at $43,000 after buying an additional 901 shares during the last quarter. Institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.